Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
Targeted Oncology · 2024-07 · 19 (4) · 645-659
DOI: 10.1007/s11523-024-01061-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Targeted Oncology, online erschienen am 30.04.2024. Verfasst von Mara Persano und 59 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy. marapersano@alice.it. Hauptthemen laut MEDLINE: Bevacizumab, Antibodies, Monoclonal, Humanized, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Università degli Studi di Cagliari.
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND: In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and widely investigated. From other pathological settings, we are aware of the prognostic and predictive value of the occurrence of immune-related AEs in patients treated with immune-checkpoint inhibitors. OBJECTIVE: This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in patients with HCC treated with atezolizumab plus bevacizumab in the first-line setting. PATIENTS AND METHODS: The study population consisted of 823 patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea). RESULTS: Of the patients, 73.3% presented at least one AE during the study period. The most common AEs were proteinuria (29.6%), arterial hypertension (27.2%), and fatigue (26.0%). In all, 17.3% of the AEs were grade (G) 3. One death due to bleeding was reported. The multivariate analysis confirmed the appearance of decreased appetite G < 2 [versus G ≥ 2; hazard ratio (HR) 0.60; 95% confidence interval (CI) 0.13-0.90; p < 0.01] and immunotoxicity G < 2 (versus G ≥ 2; HR: 0.70; 95% CI 0.24-0.99; p = 0.04) as independent prognostic factors for overall survival, and the appearance of decreased appetite G < 2 (versus G ≥ 2; HR: 0.73; 95% CI 0.43-0.95; p = 0.01), diarrhea (yes versus no; HR: 0.57, 95% CI 0.38-0.85; p = 0.01), fatigue (yes versus no; HR: 0.82, 95% CI 0.65-0.95; p < 0.01), arterial hypertension G < 2 (versus G ≥ 2; HR: 0.68, 95% CI 0.52-0.87; p < 0.01), and proteinuria (yes versus no; HR: 0.79, 95% CI 0.64-0.98; p = 0.03) as independent prognostic factors for progression-free survival. CONCLUSIONS: As demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy. marapersano@alice.it.
- Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan.
- Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Förderung
- Università degli Studi di Cagliari
Zitieren
APA
Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Rossari, F., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., Masi, G., Bergamo, F., Amadeo, E., Vitiello, F., Kumada, T., Sakamoto, N., Iwamoto, H., …, & Itokawa, N. (2024). Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab. Targeted Oncology, 19(4), 645-659. https://doi.org/10.1007/s11523-024-01061-0
Vancouver
Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, et al. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab. Targeted Oncology. 2024;19(4):645-659. doi:10.1007/s11523-024-01061-0
BibTeX
@article{Persano2024,
author = {Persano, Mara and Rimini, Margherita and Tada, Toshifumi and Suda, Goki and Shimose, Shigeo and Kudo, Masatoshi and Rossari, Federico and Yoo, Changhoon and Cheon, Jaekyung and Finkelmeier, Fabian and Lim, Ho Yeong and Presa, José and Masi, Gianluca and Bergamo, Francesca and Amadeo, Elisabeth and Vitiello, Francesco and Kumada, Takashi and Sakamoto, Naoya and Iwamoto, Hideki and Aoki, Tomoko and Chon, Hong Jae and Himmelsbach, Vera and Iavarone, Massimo Alberto and Cabibbo, Giuseppe and Montes, Margarida and Foschi, Francesco Giuseppe and Vivaldi, Caterina and Soldà, Caterina and Sho, Takuya and Niizeki, Takashi and Nishida, Naoshi and Steup, Christoph and Bruccoleri, Mariangela and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Fukunishi, Shinya and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Ochi, Hironori and Yasuda, Satoshi and Toyoda, Hidenori and Ogawa, Chikara and Nishimura, Takashi and Hatanaka, Takeshi and Kakizaki, Satoru and Shimada, Noritomo and Kawata, Kazuhito and Hiraoka, Atsushi and Tada, Fujimasa and Ohama, Hideko and Nouso, Kazuhiro and Morishita, Asahiro and Tsutsui, Akemi and Nagano, Takuya and Itokawa, Norio},
title = {Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab},
journal = {Targeted Oncology},
year = {2024},
volume = {19},
number = {4},
pages = {645--659},
doi = {10.1007/s11523-024-01061-0}
}
EUVIMED